Teva presents first real-world data from the impact-td registry study at psych congress elevate 2024

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced new patient- and physician-reported interim results from the phase 4 impact-td registry study, reinforcing that td has a wide-reaching, multidimensional impact on patients' quality of life. these interim findings from the impact-td study were presented at the 2024 psych congress elevate annual meeting, taking place from may 30.
TEVA Ratings Summary
TEVA Quant Ranking